Chronic kidney disease

U.S. Company Announces Revolutionary AI Treatment for Alzheimer's at the Microcaps Conference

Retrieved on: 
Tuesday, January 23, 2024
Diabetes, Record, Patient, Dementia, Risk, MD, Medicare Advantage, Artificial intelligence, Health, DNA, Medicare, AI, MBA, Chronic kidney disease, Conference, NIH, Harvard University, Amnesia, ATCA, Marketing, Brain, Ageing, Depression, Physician, Pharmaceutical industry

Alzheimer's Treatment Centers of America (ATCA) only treats Alzheimer's, Dementia, Cognitive Impairment and Brain Fog from Long COVID, using Artificial Intelligence combined with Personalized Precision Medicine. In the study of its AI protocol, 75% of the patients had no further decline in their mild cognitive impairment.

Key Points: 
  • ATCA's mission to treat Alzheimer's, dementia, memory loss and brain fog from Long COVID that will reshape healthcare for the aging population.
    "
  • Alzheimer's Treatment Centers of America is not a start-up; it is a roll out and it is ready to scale.
  • Alzheimer's Treatment Centers of America uses Expert Artificial Intelligence (AI) technology with AI tools to create personalized care plans aimed at helping physicians improve patient care while also satisfying cognitive care guidelines.
  • Alzheimer's Treatment Centers of America has invested $1.5 million in onsite treatment tools and modalities, a pharma-grade nutraceutical store onsite, along with a 20-chair infusion center.

Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference

Retrieved on: 
Monday, January 29, 2024
Guggenheim, Chronic kidney disease, Therapy, Conference, CKD, Hypertension

RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that Chief Executive Officer Jon Congleton will be participating in a fireside chat at the Guggenheim Securities 6th Annual Biotechnology Conference, being held in New York City on February 7-8, 2024.

Key Points: 
  • RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that Chief Executive Officer Jon Congleton will be participating in a fireside chat at the Guggenheim Securities 6th Annual Biotechnology Conference, being held in New York City on February 7-8, 2024.
  • Guggenheim Securities 6th Annual Biotechnology Conference:

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

Retrieved on: 
Tuesday, January 23, 2024
CMC, LOS, Dialysis, Patient, Therapy, International Society of Nephrology, NKF, National Kidney Foundation, ATP, Agency, Hyperphosphatemia, American Journal, Acute kidney injury, Nephrology, Clutch (eggs), ISN, Trial of the century, Society, Kidney disease, Chronic kidney disease, Water, NDA, European Renal Association, HIV/AIDS, CKD, Conditional sentence, Heart, FDA, Tablet, ERA, Letter, Patent, International Society, Mitochondrial disease, Diabetes, Physician, Pharmaceutical industry

LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today issued a letter to shareholders.

Key Points: 
  • As I sit down to write this letter, I am filled with a profound sense of gratitude and excitement, energized for the year ahead.
  • In this letter, I am pleased to recap for you another year of great accomplishments.
  • We’ve made significant advancements in our clinical programs which will propel us to new heights in 2024.
  • I would like to express my deep appreciation to the physician investigators, study participants, and especially to our dedicated Unicycive employees.

Calluna Pharma Launches and Announces EUR 75 Million Series A Financing to Develop Novel Therapies for Inflammatory and Fibrotic Diseases

Retrieved on: 
Tuesday, January 23, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Phospholipid, Pharma, Patient, Therapy, Damage-associated molecular pattern, DAMP, Idiopathic pulmonary fibrosis, Complementarity, Rheumatoid arthritis, Asthma, Scleroderma, Immune system, MBA, Chronic kidney disease, Disease, EUR, Doctor of Philosophy, General partnership, Pharmaceutical industry

Calluna has raised EUR 75 million in a series A financing and is backed by Oxitope and Arxx’s existing lead investors, Forbion, Sarsia, p53, and Investinor.

Key Points: 
  • Calluna has raised EUR 75 million in a series A financing and is backed by Oxitope and Arxx’s existing lead investors, Forbion, Sarsia, p53, and Investinor.
  • Calluna is developing novel therapies that harness the transformative potential of the body's immune system.
  • As a result, Calluna has developed a robust pipeline of selective antibodies, targeting immunological diseases.
  • The Company is raising further financing to develop its pipeline to multiple key clinical milestones over the next 2.5 years.

Injectable Angioplasty Balloon Catheter Transforms Peripheral Procedures, Users Report Reduced Equipment and Contrast Needs

Retrieved on: 
Wednesday, January 17, 2024
Medical Devices, Surgery, FDA, Clinical Trials, Cardiology, Practice Management, Other Health, Biotechnology, Radiology, Health, Diabetes, Patient, Amputation, Kidney, Calf, Knee, Finesse, Angiography, Multimedia, DRS, Risk, Chronic kidney disease, Mount Sinai Hospital (Manhattan), PAD, Medical imaging

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    The Summa Finesse Injectable catheter is the industry’s first hybrid diagnostic and therapeutic angioplasty balloon catheter developed to facilitate treatment of patients at risk of limb loss due to below-knee PAD.
  • It was designed to improve the efficiency of peripheral angioplasty procedures by reducing equipment and contrast needs.
  • “In our busy limb salvage practice, it will be an important tool.”
    The Summa Finesse Injectable is a multifunctional catheter that serves as a crossing catheter, diagnostic angiography catheter, and angioplasty catheter to reduce equipment and contrast needs.
  • The Summa Finesse Injectable is the first hybrid catheter launched in the planned line of interventional radiology devices from Summa.

First Implantation of VasQ External Support Device in Greece

Retrieved on: 
Tuesday, January 23, 2024
Patient, Fistula, Gilon, International, Vascular access, Lamination, Chronic kidney disease, Physician

ATHENS, Greece, Jan. 23, 2024 /PRNewswire/ -- The first implantation of the VasQ™ external support device in Greece was successfully performed by Dr. Alexandros Mallios at Henry Dunant Hospital Center in Athens, Greece.

Key Points: 
  • ATHENS, Greece, Jan. 23, 2024 /PRNewswire/ -- The first implantation of the VasQ™ external support device in Greece was successfully performed by Dr. Alexandros Mallios at Henry Dunant Hospital Center in Athens, Greece.
  • As a visiting surgeon, Dr. Mallios worked with the center's physicians to introduce VasQ to patients served by the Henry Dunant Hospital Center.
  • The device is unique in that it is implanted around the artery-vein connection to provide permanent external support to the mobilized venous segment, which is the typical site of early fistula failure.
  • Laminate CEO Tammy Gilon expressed her enthusiasm for the successful inaugural VasQ case in Greece.

Point32Health and Monogram Health Expand Collaboration Aimed at Improving Chronic Kidney Care

Retrieved on: 
Tuesday, January 16, 2024
Patient, African Americans, MD, Health, Tufts Health Plan, Kidney disease, Monogram, Quality of life, Harvard Pilgrim Health Care, Chronic kidney disease, CKD, ESKD, Nursing

and NASHVILLE, Tenn., Jan. 16, 2024 /PRNewswire/ -- Point32Health , the parent company of Tufts Health Plan and Harvard Pilgrim Health Care, today announced an expansion of its relationship with Monogram Health , the nation's leading value-based provider of in-home, evidence-based care and benefit management services for patients living with chronic kidney and end stage kidney disease to include members in its Tufts Health Direct population.

Key Points: 
  • and NASHVILLE, Tenn., Jan. 16, 2024 /PRNewswire/ -- Point32Health , the parent company of Tufts Health Plan and Harvard Pilgrim Health Care, today announced an expansion of its relationship with Monogram Health , the nation's leading value-based provider of in-home, evidence-based care and benefit management services for patients living with chronic kidney and end stage kidney disease to include members in its Tufts Health Direct population.
  • Point32Health and Monogram began working together in 2022 to improve early access to kidney care for Harvard Pilgrim Health Care and Tufts Health commercial members.
  • Through the expanded collaboration, Monogram Health will assume full financial risk for Tufts Health Direct members with kidney disease, delivering industry-leading in-home specialty care services, promoting better patient outcomes while improving affordability.
  • "This powerful collaboration with Point32Health expands Monogram's ability to transform health care for CKD and ESKD patients in the commercial space," said Aash Shah, MD, chief growth officer of Monogram Health.

Boehringer expands production site in Greece for new medicine

Retrieved on: 
Thursday, January 11, 2024
Patient, Professional, Corporate headquarters, Chronic liver disease, Boehringer, Scleroderma, Heart failure, Government, Mental health, Research and development, Pulmonary fibrosis, Chronic kidney disease, CRM, EUR, Boehringer Ingelheim, Workforce

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece.

Key Points: 
  • Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece.
  • Greek Prime Minister Kyriakos Mitsotakis attended the groundbreaking ceremony at the Koropi site today, alongside the Minister of State, the Minister of Health and the Minister of Development.
  • In 2020, the company announced multi-year investments to expand the site and its production capacity.
  • The Koropi plant is the only industrial facility of a multinational pharmaceutical company in Greece producing innovative medicines.

New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease

Retrieved on: 
Wednesday, January 10, 2024
Diabetes, RWE, American Heart Association, Patient, Diabetic nephropathy, Kidney, MD, Hypertension, Risk assessment, Type 2 diabetes, Insurance, Heart failure, Risk, Food, Chronic kidney disease, Real world evidence, CKD, Community health, FDA, Doctor of Philosophy, BMI, Real, EGFR, Marketing, Physician, Pharmaceutical industry

LONDON and SALT LAKE CITY, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces publication of Real World Evidence (“RWE”) after 12 months of follow-up in 2,569 patients with Type 2 diabetes and diabetic kidney disease (“DKD”) at a major U.S. health system in Primary Care and Community Health. Results in the diverse cohort, including 27% black patients, demonstrate that electronic health record deployment of KidneyIntelX in vitro prognostic testing was associated with clinical actions that led to a significant slowing of chronic kidney disease progression and improved Type 2 diabetes control most notably in the highest risk patients.

Key Points: 
  • Improved kidney health was evidenced by reduction in the rate of kidney function decline (eGFR slope) and diabetes control was evidenced by improved A1C levels.
  • KidneyIntelX testing achieved scale through electronic health record integration, deploying directly to large treating groups of primary care physicians.
  • KidneyIntelX has received broad insurance payment coverage including through Medicare, Medicaid, and Blue Cross Blue Shield programs.
  • “The demonstrated benefits of KidneyIntelX early risk assessment at one year are significant and go to the core of chronic disease preventative medicine.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform

Retrieved on: 
Tuesday, January 9, 2024
Diabetes, LEXX, Chronic kidney disease, Invention, Research, NNW, Addiction, Weight loss, Pharmaceutical industry

Obviously, diabetes remains a primary indication, given the massive global need.

Key Points: 
  • Obviously, diabetes remains a primary indication, given the massive global need.
  • However, the impact of this extraordinary molecule extends far beyond type 2 diabetes.
  • The reach of GLP-1 drugs has widened in ways its inventors likely never imagined.
  • The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies.